An Extension Long-Term Safety and Tolerability Trial of Degarelix, Following a 1-year Open-Label, Multi-Centre, Randomised, Parallel-group Trial in Which the Efficacy and Safety of Degarelix One-month Dosing Regimen Was Compared With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Registrational
- Acronyms PandaExtension
- Sponsors Ferring Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Status changed from active, no longer recruiting to completed.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.